Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PARP inhibitor
Biotech
AACR: AstraZeneca PARP inhibitor gives 'bang for your buck'
First-in-human results for AstraZeneca's saruparib showed an objective response rate of 48.8% in 31 patients.
Annalee Armstrong
Apr 9, 2024 5:00am
Incyte vets raise $102M to create better PARP, PI3K drugs
Jan 24, 2024 8:38am
Gilead picks up small PARP1 biotech to find a mate for Trodelvy
May 9, 2023 10:44am
Junshi's Lynparza rival hits mark in ovarian cancer phase 3
Apr 12, 2023 5:30am
Roche pays Repare $125M to join Big Pharma peers in cancer race
Jun 2, 2022 8:27am
AstraZeneca re-ups ties with Chinese cancer test maker AmoyDx
Apr 18, 2022 10:42am
